Gayatri BioOrga.

Why is Gayatri BioOrganics Ltd falling/rising?

As of 01-Sep, Gayatri BioOrganics Ltd's stock price is at 7.44, down 0.8%, with a year-to-date decline of 57.82% and negative financial indicators suggesting weak long-term prospects and reduced investor interest. The stock is trading below all major moving averages, indicating a bearish trend.

As of 01-Sep, Gayatri BioOrganics Ltd's stock price is currently at 7.44, reflecting a decrease of 0.06 or 0.8%. The stock has been underperforming in the market, as evidenced by its performance today, where it underperformed its sector by 0.38%. Over the past week, the stock has shown a slight increase of 0.54%, but this is overshadowed by its year-to-date decline of 57.82%, indicating significant long-term challenges.<BR><BR>The company has a negative book value of Rs 37.00 crore and has recorded a negative EBITDA of Rs. -0.75 crore, which points to weak long-term fundamental strength. Additionally, its net sales growth has been stagnant, and it has generated a return of -36.57% over the past year, highlighting poor performance compared to the broader market, including the BSE500 index.<BR><BR>Investor participation has also declined, with delivery volume dropping by 77.9% against the 5-day average, suggesting waning interest from investors. The stock is trading below its 5-day, 20-day, 100-day, and 200-day moving averages, further indicating a bearish trend. Overall, the combination of negative financial indicators, poor long-term growth prospects, and reduced investor participation contributes to the stock's falling price.

Who are in the management team of Gayatri BioOrga.?

The management team of Gayatri BioOrga includes T V Sandeep Kumar Reddy (Executive Chairman), Murali Vittala, P V Narayana Rao, Ch Ramachandra Seshaprasad (all Independent Directors), K. Sridhar Reddy (Whole-time Director), Meenakshi Ramchand Sachdeva (Director), and Aamir Tak (Company Secretary & Compliance Officer).

The management team of Gayatri BioOrga includes the following members:<BR><BR>1. T V Sandeep Kumar Reddy - Executive Chairman<BR>2. Murali Vittala - Independent Director<BR>3. P V Narayana Rao - Independent Director<BR>4. Ch Ramachandra Seshaprasad - Independent Director<BR>5. K. Sridhar Reddy - Whole-time Director<BR>6. Meenakshi Ramchand Sachdeva - Director<BR>7. Aamir Tak - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Gayatri BioOrga. do?

Gayatri BioOrganics Ltd is a micro-cap company in the commodity chemicals industry, previously known as Starchem Industries. As of June 2026, it reported net sales of 2 Cr and a market cap of INR 61 Cr.

Overview:<BR>Gayatri BioOrganics Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Starchem Industries Limited' in 1991, changed its name to Gayatri Starchem Limited in 1997, and was renamed Gayatri BioOrganics Limited in 2008. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 2 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 61 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.02 <BR>Return on Equity: 2.73% <BR>Price to Book: -1.61 <BR><BR>Contact Details:<BR>Address: 6-3-1090 B-Block 3rd Floor, TSRTowers Rajbhavan Rd Somajiguda Hyderabad Telangana : 500082 <BR>Tel: 91-40-66100111 <BR>Email: info@gayatribioorganics.com <BR>Website: http://www.gayatribioorganics.com

Who are the peers of the Gayatri BioOrga.?

Peers of Gayatri BioOrga. include Archit Organosys, Sh. Hari Chem., AG Ventures, Polychem, Ritesh Intl., Shreyas Interm., Camex, TCM, and Haryana Leather. Sh. Hari Chem. has the highest 1-year return at 101.43%, while Gayatri BioOrga. has a return of -37.50%.

Peers: The peers of Gayatri BioOrga. are Archit Organosys, Sh. Hari Chem., AG Ventures, Polychem, Ritesh Intl., Shreyas Interm., Camex, TCM, and Haryana Leather.<BR><BR>Quality Snapshot: Excellent management risk is observed at AG Ventures, while Average management risk is found at Sh. Hari Chem. and Ritesh Intl., and the rest have Below Average management risk. Good growth is noted at Sh. Hari Chem., while Average growth is found at Shreyas Interm. and the rest have Below Average growth. Excellent capital structure is seen at AG Ventures, while Good capital structure is noted at Polychem and Haryana Leather, Average capital structure is found at Ritesh Intl., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sh. Hari Chem. at 101.43%, while the lowest is AG Ventures at -19.62%, with Gayatri BioOrga.'s own 1-year return at -37.50% being lower than both. Additionally, peers such as Polychem, Shreyas Interm., and Haryana Leather have negative six-month returns.

How big is Gayatri BioOrga.?

As of 31st August, Gayatri BioOrganics Ltd has a market capitalization of 61.00 Cr and reported Net Sales of 2.34 Cr with a Net Profit loss of 0.95 Cr over the latest four quarters. Shareholder's Funds showed a loss of 35.89 Cr against Total Assets of 1.66 Cr.

As of 31st August, Gayatri BioOrganics Ltd has a market capitalization of 61.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2.34 Cr. However, it experienced a loss of 0.95 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds were recorded at a loss of 35.89 Cr, while Total Assets amounted to 1.66 Cr.

Which are the latest news on Gayatri BioOrga.?

Are Gayatri BioOrganics Ltd latest results good or bad?

Gayatri BioOrganics Ltd's latest results are concerning, showing a marginal revenue of ₹2.34 crores but a net loss of ₹0.10 crores and negative equity of ₹-4.56 per share, indicating significant financial distress and ongoing operational struggles.

The latest results for Gayatri BioOrganics Ltd indicate a challenging financial situation. While the company reported its first revenue in seven quarters, amounting to ₹2.34 crores in Q1 FY27, it still faced significant losses, with a net profit of ₹-0.10 crores. This reflects continued operational struggles despite the marginal revenue generation.<BR><BR>The company's operating profit was just ₹0.01 crores, which was completely offset by interest costs of ₹0.11 crores, highlighting its inability to cover even basic financial obligations. Additionally, Gayatri BioOrganics has a negative book value of ₹-4.56 per share and a market capitalization of only ₹58.85 crores, indicating severe financial distress and technical insolvency.<BR><BR>Overall, while there was a slight glimmer of activity with the emergence of revenue, the underlying financial health remains precarious, and the results can be characterized as bad given the ongoing losses and negative equity position.

Should I buy, sell or hold Gayatri BioOrganics Ltd?

When is the next results date for Gayatri BioOrganics Ltd?

The next results date for Gayatri BioOrganics Ltd is August 4, 2026.

The next results date for Gayatri BioOrganics Ltd is scheduled for August 4, 2026.

How has been the historical performance of Gayatri BioOrga.?

Gayatri BioOrga has faced significant financial challenges, reporting minimal revenue and consistent losses, with net sales dropping to zero in 2024 and 2025, and negative reserves of -114.68 Cr by March 2025. The company has not generated any cash flow from operations since March 2020.

Answer:<BR>The historical performance of Gayatri BioOrga shows a challenging trend with minimal revenue generation and consistent losses over the years.<BR><BR>Breakdown:<BR>Gayatri BioOrga reported net sales of 1.67 Cr in March 2023, but this figure dropped to 0.00 Cr in both March 2024 and March 2025, indicating a complete halt in revenue generation. The total operating income mirrored this trend, remaining at 0.00 Cr for the last two years after a peak in March 2023. The company's expenditures, excluding depreciation, were 2.44 Cr in March 2023, decreasing to 0.45 Cr by March 2025, yet the operating profit continued to be negative, with losses of -0.45 Cr in March 2025 compared to -0.77 Cr in March 2023. The profit before tax also remained negative, with a loss of -0.73 Cr in March 2025. The company's reserves have been in a negative state, reaching -114.68 Cr in March 2025, while shareholder's funds also reflected a negative balance of -35.89 Cr. Cash flow from operating activities has been non-existent since March 2020, with no cash inflow or outflow reported in the last three years. Overall, Gayatri BioOrga's financial performance indicates significant operational challenges and a lack of profitability.

Is Gayatri BioOrga. overvalued or undervalued?

As of April 25, 2023, Gayatri BioOrga is classified as risky and overvalued, with negative key ratios indicating financial struggles, despite a 34.16% return over the past year, outperforming the Sensex's 7.57%.

As of 25 April 2023, the valuation grade for Gayatri BioOrga. has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -58.43, an EV to EBIT of -95.74, and a ROCE of -38.46%. <BR><BR>In comparison to peers, Solar Industries is classified as very expensive with a PE ratio of 123.77, while Godrej Industries is attractive with a PE ratio of 46.63. The significant negative ratios for Gayatri BioOrga. suggest that the company is struggling financially, which is reflected in its poor performance relative to the Sensex, although it has outperformed the index over the past year with a return of 34.16% compared to the Sensex's 7.57%.

What is the technical trend for Gayatri BioOrga.?

As of May 14, 2025, Gayatri BioOrga's technical trend is bullish, supported by strong daily and weekly indicators, despite mild bullishness in the monthly MACD and KST.

As of 14 May 2025, the technical trend for Gayatri BioOrga has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate a bullish stance. The weekly KST is bullish, further reinforcing the upward momentum. Although the monthly MACD and KST are only mildly bullish, the overall strength of the trend is supported by the daily indicators. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting a potential for continued upward movement. The Dow Theory shows a mildly bullish trend on the weekly chart, but no trend on the monthly. Overall, the current technical stance is bullish with strong indicators from the daily and weekly time frames.

Who are the top shareholders of the Gayatri BioOrga.?

The top shareholders of Gayatri BioOrga include promoter Sandeep Kumar Reddy Tikkavarapu with 21.59% and public shareholder Fursa Mauritius Spv 1 with 23.48%. Individual investors hold 53.01% of shares, while mutual funds and foreign institutional investors hold minor stakes.

The top shareholders of Gayatri BioOrga include Sandeep Kumar Reddy Tikkavarapu, who is the promoter with the highest holding at 21.59%. Additionally, the highest public shareholder is Fursa Mauritius Spv 1, holding 23.48%. Individual investors collectively hold 53.01% of the shares. The company also has some mutual fund representation, with three schemes holding 0.65%, and one foreign institutional investor holding 0.01%. There are no pledged promoter holdings reported.

Has Gayatri BioOrga. declared dividend?

No Dividend History Available